X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Tri-Ad5 vaccine combination (hAd5 CEA/MUC1/brachyury) together with its IL-15 superagonist and immune enhancer N-803 is being evaluated in people with Lynch syndrome.
Lead Product(s): Ad5 CEA/MUC1/Brachyury Vaccine Tri-Ad5,Nogapendekin Alfa
Therapeutic Area: Oncology Product Name: Tri Ad5
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
The proceeds will also be used to fund company's clinical trials expanding N-803 (Anktiva), an interleukin-15 superagonist fusion protein, being developed for indications into multiple solid tumors, including BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Oberland Capital
Deal Size: $320.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 02, 2024
Details:
Anktiva (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
Anktiva (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
The financing will fund company's ongoing business operations and pre-commercialization efforts as it continues to drive toward a potential regulatory approval of Anktiva (N-803), a novel IL-15 superagonist, plus BCG for BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nant Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing September 11, 2023
Details:
Anktiva™ (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex and which is investigated for advanced Head-and-Neck Cancer Patients.
Lead Product(s): Cytokine Induced Memory-Like Natural Killer Cell,Nogapendekin alfa Inbakicept
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Dana-Farber Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
Tri-Ad5 targets three tumor-associated antigens, brachyury, CEA and mucin-1. It elicits cytotoxic T cell-mediated tumor cell death and the establishment of memory T cells, providing protection against the growth and metastasis of cancer in combination with N-803.
Lead Product(s): Tri-Ad5,Nogapendekin alfa Inbakicept
Therapeutic Area: Oncology Product Name: Tri-Ad5
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
Anktiva™ (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex and has received breakthrough therapy and fast track designations from the U.S. FDA for BCG-unresponsive CIS non-muscle invasive bladder cancer.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
N-803 (anktiva), ImmunityBio’s lead cytokine fusion protein, is a novel IL-15 superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. FDA for BCG-unresponsive CIS non-muscle invasive bladder cancer.
Lead Product(s): N-803,BCG
Therapeutic Area: Oncology Product Name: N-803
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Piper Sandler & Co.
Deal Size: $110.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 12, 2022
Details:
Positive QUILT 3.032 trial for Anktiva (N-803) results in 71% of BCG-unresponsive NMIBC patients who had failed on previous therapies showed complete response with duration of 26.6 months; cystectomy avoidance rate of 91% and 100% bladder cancer overall survival at 24 months.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
